WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of MK-0677 in the manufacture of a medicament for the treatment of growth hormone deficiency (GHD) in children known to have short stature and equivalent growth potential compared to rhGH,

wherein the therapeutically effective amount is 0.1-2.0 mg/kg/d and a child has equivalent growth potential compared to rhGH when the child has:

(i.) a peak serum GH ≥5 μg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

2. The use of Claim 1, wherein a single 0.8 mg/kg/d dose of MK-0677 is to be administered orally.

3. The use of Claim 1, wherein at least one mini-tablets, comprising: MK-0677 is to be administered orally.

4. The use of Claim 3, wherein the mini-tablet, comprises: 2 mg of MK-0677.

5. The use of Claim 1, wherein the GHD is pediatric GHD.

6. The use of Claim 1, wherein MK-0677 is for to be administered orally with the assistance of a device capable of dispensing at least one MK-0677 mini-tablet.

7. Use of a therapeutically effective amount of MK-0677 in the manufacture of a medicament for the treatment of

GHD in children found from a theranostic test to have short stature and equivalent growth potential compared to rhGH;

wherein the therapeutically effective amount is 0.1-2.0 mg/kg/d and a child has equivalent growth potential compared to rhGH when the child has:

(i.) a peak serum GH ≥5 µg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

8. The use of Claim 7, wherein a single, 0.8 mg/kg/d dose of MK-0677 is to be administered orally.

9. The use of Claim 7, wherein at least one mini-tablet[s], comprising: MK-0677 is to be administered orally.

10. The use of Claim 5, wherein the mini-tablet, comprises: 2 mg of MK-0677.

11. The use of Claim 7, wherein the therapeutically effective amount of MK-0677 is to be administered orally with the assistance of a device capable of dispensing at least one MK-0677 mini-tablet.

12. The use of Claim 7, wherein the GHD is pediatric GHD.

13. The use of Claim 7, wherein the children found from a theranostic test to have short stature and equivalent growth potential compared to rhGH, comprises:

(i.) a peak serum GH of ≥5 µg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

14. The use of Claim 13, wherein the single oral dose of MK-0677 is 0.8 mg/kg/d.

15. The use of Claim 1, wherein the therapeutically effective amount is 0.8 mg/kg/d of MK-0677.

16. The use of Claim 1, wherein the therapeutically effective amount is 1.6 mg/kg/d of MK-0677.

17. The use of Claim 7, wherein the therapeutically effective amount is 0.8 mg/kg/d of MK-0677.

18. The use of Claim 7, wherein the therapeutically effective amount is 1.6 mg/kg/d of MK-0677.

19. The use of Claim 3, wherein the mini-tablet, comprises: 4 mg of MK-0677.

20. The use of Claim 9, wherein the mini-tablet, comprises: 4 mg of MK-0677.

21. The use of Claim 1, wherein the treatment is to be maintained for more than 6 months.

22. The use of Claim 1, wherein the treatment is to be maintained for at least 7 months.

23. The use of Claim 1, wherein the treatment is to be maintained until growth potential is exhausted.

24. The use of Claim 7, wherein the treatment is to be maintained for more than 6 months.

25. The use of Claim 7, wherein the treatment is to be maintained for at least 7 months.

26. The use of Claim 7, wherein the treatment is to be maintained until growth potential is exhausted.